Chumsri, Saranya http://orcid.org/0000-0001-7117-1446
Li, Zhuo
Serie, Daniel J.
Norton, Nadine
Mashadi-Hossein, Afshin http://orcid.org/0000-0002-2337-2195
Tenner, Kathleen
Brauer, Heather Ann
Warren, Sarah
Danaher, Patrick http://orcid.org/0000-0002-2844-5883
Colon-Otero, Gerardo
Partridge, Ann H. http://orcid.org/0000-0002-4722-4824
Carey, Lisa A. http://orcid.org/0000-0003-2388-4649
Hilbers, Florentine
Van Dooren, Veerle
Holmes, Eileen
Di Cosimo, Serena
Werner, Olena
Huober, Jens Bodo
Dueck, Amylou C.
Sotiriou, Christos http://orcid.org/0000-0002-5745-9977
Saura, Cristina
Moreno-Aspitia, Alvaro
Knutson, Keith L. http://orcid.org/0000-0001-9932-4467
Perez, Edith A.
Thompson, E. Aubrey http://orcid.org/0000-0002-9001-4240
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U10CA180882, U24CA196171, UG1CA233180, UG1CA232760, UG1CA233373, U10CA180821, U10CA180882, U24CA196171, UG1CA233180, UG1CA232760, UG1CA233373, U10CA180821, U10CA180882, U24CA196171, UG1CA233180, UG1CA232760, UG1CA233373, U10CA180821)
U.S. Department of Defense (W81XWH-18-1-0562, W81XWH-16-1-0265, W81XWH-18-1-0562, W81XWH-16-1-0265, W81XWH-18-1-0562, W81XWH-16-1-0265)
Breast Cancer Research Foundation (BCRF-19-161)
Bankhead-Coley Foundation (6BC05, 6BC05)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Article History
Received: 10 August 2021
Accepted: 19 March 2022
First Online: 24 May 2022
Competing interests
: There are no relevant conflicts of interest for Ms. Li, Mr. Serie, Ms. Tenner, Mr. Gavin, Ms. Van Dooren, Ms. Holmes, and Drs. Norton, Partridge, Carey, Hilbers, Holmes, Di Cosimo, Dueck, Sotirios, Knutson, and Thompson. Dr. Chumsri receives institutional research funding from Merck & Co. and Pfizer. Mr. Mashadi-Hossein, Drs. Brauer, Warren, and Danaher worked at NanoString Technologies, Inc. Dr. Werner worked at Novartis. Dr. Colon-Otero receives funding support for investigator-initiated trial from Novartis. Dr. Huober receives funding support from Novartis, honoraria, consulting advisory relationship, and travel expenses from Novartis and Roche. Dr. Perez worked at Genentech. Dr. Moreno-Aspitia receives institutional research funding from Genentech, GSK, Sermonix, and Daiichi.